Blog Archives

Our novel sea lice vaccine research leaps forward to next stage and makes waves in aqua media.

3/28/2024

🌟 Innovation Through Collaboration: A Leap Forward
in Sea Lice Vaccine Research 🌟

All the Team in AQUATRECK ANIMAL HEALTH S.L, we are thrilled to share a pivotal milestone on the development of a groundbreaking vaccine against sea lice, that is making news with the project successfully progressing to its next phase, thanks to almost £50,000 in funding from Sustainable Aquaculture Innovation Centre (SAIC) in collaboration with the University of Stirling’s Institute of Aquaculture and Moredun Scientific.  This milestone is a testament to the promising outcomes of our initial proof-of-concept phase, which unveiled that a novel vaccine technology based on yeast expression technology can create recombinant proteins that can trigger an immune response and create elevated antibody levels in the bloodstream of fishthat aim to impair sea lice development and potentially reduce the number of parasite offspring by mature sea lice.

AQUATRECK ANIMAL HEALTH S.L novel yeast expression platform can support scalling up of vaccine production with the aim to address the global aquaculture challenge posed by sea lice, with costs amounting to up to $1 billion per year.  The essence of our project lies not only in the innovative approach to vaccine development but also in the power of collaboration. By bringing together the expertise and dedication of our partners, we are paving the way for a solution that promises to enhance fish health and welfare significantly, reduce environmental impact, and create a more economically viable future for the salmon farming sector. The team is using advanced recombinant expression technology for injection vaccination and, if successful, the technology could be scaled up to make mass antigens available to later be applied via salmon feeds as an oral vaccine.
We extend our heartfelt thanks to Sustainable Aquaculture Innovation Centrefor their financial support and faith in our project's potential.
Our gratitude also goes out to Dr Sean Monaghan and all our partners at the University of Stirling’s Institute of Aquaculture and Moredun Scientific, whose expertise has been invaluable in reaching this stage of research. Together, we are not just aiming to tackle one of aquaculture's biggest challenges but also to set a precedent for how collaboration can lead to meaningful innovation.
As we move forward, AQUATRECK ANIMAL HEALTH S.L remains committed to this project's success and the broader goal of promoting sustainable aquaculture globally. We look forward to sharing more milestones and, ultimately, the positive impact of our vaccine on the aquaculture industry.  Special thanks to the aquaculture media that brought forward the news and SAIC Team for making the announcement.  Thank you to everyone involved for your dedication, expertise, and vision. Together, we are making a difference.

0 Comments

Juan Carlos Castillejo joins Aquatreck Board

3/28/2024

0 Comments

🌟 Exciting Announcement from AQUATRECK ANIMAL
HEALTH S.L.🌟

It is a great honor and pleasure to welcome Juan Carlos Castillejo in the Board of Directors of AQUATRECK ANIMAL HEALTH S.L. to support our dynamic fish vaccine company with his strategic thinking in the implementation of our growth strategy. 🚀

Juan Carlos is a leader in animal health with extensive professional experience in senior management of animal health biopharmaceutical companies.

Juan Carlos holds a degree in Biological Sciences from the Universidad Autónoma de Madrid, a degree in Veterinary Medicine from the Universidad Complutense de Madrid and a Master's degree in Business Administration from the Instituto de Empresa, joined the MSD Animal Health in 2013 to take up the position of Managing Director in Spain and in 2014 he became Managing Director of the Iberia cluster. including Portugal.

Juan Carlos Castillejo was president of VETERINDUSTRIA for more than 10 years, he held the management for Spain and Portugal of the two most important multinationals in the animal health market, Zoetis (formerly Pfizer Animal Health) and MSD Animal Health were he closed his professional career after ten years as Managing Director of MSD Animal Health in Spain and Portugal at the end of 2022.

In this position he led the digital transformation of the organization and adapted the company, developing the capabilities required for the future. One of the main achievements of his business career was the development and commercialization of the world's first bluetongue vaccine. Juan Carlos joined Grupo ZENDAL's steering committee as a strategic advisor in May 2023.

0 Comments